NORML

MARCH 1, 2019

… Without access to an expanded range of cannabis products engineered under FDA-approved Good Manufacturing Practices, scientific research cannot hope to keep pace with the ever expanding recreational and medicinal cannabis marketplace.” ” The APA represents nearly 120,000 researchers and clinicians. .”

DEA 198

DEA Research and Development Clinical Trials Marijuana 198

The Cannigma

MARCH 25, 2021

When the law changed in the UK in 2018, I was humbled by the efforts of those who suffer on a daily basis to achieve legal access to medicinal cannabis. Transfering nurses’ skills to cannabis medicine. The idea behind the MDT series is to place the unfamiliar cannabis medicines into a familiar case discussion format.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

AUGUST 7, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable, and accessible work environment. European Regulatory Lead Executive Summary. Key Responsibilities.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

SpeedWeed

MAY 15, 2021

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. MAPS is now enrolling participants for a further Phase 3 study that will allow another 50 subjects to access this promising new therapy. Image via.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

CannaTech

SEPTEMBER 23, 2019

This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

FEBRUARY 24, 2022

Thus, providing a new pathway for patients to access psychedelic treatment, and another example of the medicinal approach to psychedelic legalization. Timeline of Medicinal Legalization in Canada. In January 2022, the FDR statute was amended to give healthcare professionals access to restricted drugs through SAP.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

SEPTEMBER 8, 2021

Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).

Access 97

Access Research and Development Medicine THC 97

Cannabis Law Report

FEBRUARY 13, 2019

Establish a network (…) to ensure effective implementation of the strategy for cannabis-based medicines.”. Improve equal access to cannabis-based medicines.”. Ensure sufficient availability of cannabis-based medicines.”. Provide medical professionals with proper medical training.”. Source: [link]. printficheglobal.

Medicine 55

Medicine Clinical Trials Access Cannabis 55

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. At the state level, patients in Ohio and Oklahoma now have access to medical cannabis, as sales began in both states this week. Additionally, a bipartisan coalition of U.S.

Legislation 184

Legislation Decriminalization Access Therapy 184

Cannabis Law Report

JUNE 20, 2021

The CIC consists of 97 members dedicated to ensuring a greater understanding of the role of medicinal cannabis, nutraceutical CBD, and hemp across the community and the advancement of medicinal cannabis as an alternate line of therapy. Patient access.

Supply Chain 81

Supply Chain Clinical Trials Research and Development Medicine 81

Cannabis Law Report

JULY 15, 2021

Completion of acquisition provides Creso Pharma with access to the emerging global market for psychedelic medicines – estimated to be worth up to US100Bni. ? Halucenex to progress phase II clinical trial to test the efficacy of psilocybin when used to treat Post Traumatic Stress Disorder (PTSD). ? Highlights: ?

Clinical Trials 74

Clinical Trials Therapy Treatment Access 74

Project CBD

MAY 3, 2023

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. Remember, the pharmaceutical model is “this medicine addresses this specific target.”

Cannabinoids 213

Cannabinoids Sleep Clinical Trials CBD 213

Veriheal

MARCH 20, 2023

Alternative medicine is becoming more widely acknowledged and practiced than ever before, opening the door for therapies like psychedelics to enter the world of mainstream healthcare. Andy Smith (D) stated that he is “working on a bill forming a psychedelic medicine task force so Minnesotans can access these life-affirming treatments.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

MGC Pharma

FEBRUARY 20, 2018

CBD passes Stage 3 clinical trial for the treatment of epilepsy in children A study published last year in The New England Journal of Medicine saw scientists studying the effects of CBD on epileptic seizures in patients with Dravet syndrome, a severe epileptic disorder leading to frequent and uncontrollable seizures in children.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

JANUARY 14, 2022

THE Member of Parliament sponsoring the Medical Cannabis Access Bill in the House of Commons today has acknowledged it is set to fail due to lack of political support. Cannabis Trials. BusinessCann UK reports that the UK Medical Cannabis Bill has Buckley’s chance.

Access 52

Access Clinical Trials Patients Cannabis 52

Cannabis Law Report

JULY 28, 2021

This includes First Time in Human (“FTiH”) clinical trials, which are expected to commence in 2022, for the Group’s lead compound OCT461201, a selective cannabinoid receptor type 2 (“CB2”) agonist with initial indications in the areas of post herpetic neuralgia and visceral pain caused by irritable bowel syndrome.

Cannabinoids 81

Cannabinoids Clinical Trials Safety Medicine 81

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

Cannabis Law Report

AUGUST 14, 2021

The deal signed in March had sought to progress an over-the-counter medicine with the TGA using Emyria’s EMD-003 program and Cann’s Gelpell technology. Cann Group (CAN) and Emyria (EMD) mutually agree to drop a deal for the proposed registration of a Schedule 3 cannabidiol (CBD) product.

CBD 105

CBD Clinical Trials Programs Medicine 105

Cannabis Law Report

JANUARY 11, 2022

Legal cannabis partnership to help patient access. The new distributor in the Australian medicinal cannabis industry – The Entourage Effect – has signed a firstof its kind deal with innovative medical cannabis clinic MiDispensary. UPDATED : Wednesday 12th of January 2022. SYDNEY, AUSTRALIA –.

Access 52

Access Patients Clinical Trials Legalization 52

Project CBD

FEBRUARY 28, 2023

The following excerpt analyzes CBD marketing trends reported by the American Botanical Council, a membership organization that educates consumers, health care professionals, journalists, and others about the safe and effective use of medicinal plants. Accessed July 25, 2021. Available at: [link] Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

NOVEMBER 7, 2021

WA Upper House MP Brian Walker is in the spotlight over potential conflict of interests concerns after he was appointed ‘strategic consultant’ to an ASX-listed medicinal cannabis company. Legalise Cannabis WA MP Brian Walker denies conflict over medicinal cannabis company. Cannabiz reported Friday. and Halucenex Life Sciences Inc.

Medicine 52

Medicine Clinical Trials Research and Development Pharmaceutical 52

NewsMunchies

NOVEMBER 12, 2021

In clinical trials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. In Western medicine, the psychedelic revolution is coming at the perfect moment as the country grapples with a post-COVID world.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

The Cannigma

FEBRUARY 2, 2021

As medicinal cannabis treatments are now legal in many parts of the world, naturally, there is a growing interest in whether the products can treat neurological conditions like Parkinson’s disease. Patients can also access CBD products without a prescription through local pharmacies. Parkinson’s disease and cannabis.

Patients 98

Patients Clinical Trials Research and Development Treatment 98

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website. This means that U.S.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Cannabis Law Report

MARCH 2, 2020

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. The new measures will be implemented by the Home Office and the Medicines and Healthcare products Regulatory Agency (MHRA) from March 2. But we still have a long way to go.

Medicine 45

Medicine Research and Development Clinical Trials Patients 45

Cannabis Law Report

SEPTEMBER 1, 2021

CYBN ) is a Toronto-based psychedelic medicine firm. The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. At the moment, MindMed is hands-down the industry leader in LSD-inspired medicines.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

MAY 10, 2022

First comprehensive study reveals why Australians take medicinal cannabis. First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Medicinal cannabis as a last resort.

Medicine 52

Medicine Clinical Trials Sleep Data 52

The Cannigma

APRIL 12, 2023

Sleep is not often the focus of clinical trials on cannabis; rather it is often a secondary outcome. This direct access to consumers allows MoreBetter to conduct informal studies, collecting data from a set of participants with a selected product over a set amount of time. Has CBN been proven to help with sleep?

Sleep 137

Sleep Data Tincture Research and Development 137

Veriheal

JULY 7, 2023

Thankfully, a team of scientists at Medicinal Genomics may have just stumbled upon a solution. Medicinal Genomics stumbled upon the discovery that purple-colored cannabis plants appear to have a resistance to HLVd. In order to gain access to psychedelics, Australians firsts need to see a psychiatrist. Currently, the U.S.,

Legalization 97

Legalization Clinical Trials Research and Development History 97

Veriheal

MAY 26, 2022

But one area of cannabis medicine is still lagging behind—research. RoC also works to increase patients’ access to medical cannabis by helping U.S. states pass relevant legislation and educating doctors about the power of cannabis medicine. Bringing Cannabis Into Mainstream Medicine.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

MMJ Recs

JULY 9, 2024

Medical Marijuana: An Overview Medical marijuana refers to the use of cannabis and its cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), for medicinal purposes. ” Other cannabinoids, like cannabinol (CBN) and cannabigerol (CBG), also contribute to the plant’s medicinal benefits.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Cannabis Law Report

MAY 10, 2022

More than half of all prescriptions for medicinal cannabis in Australia are written by doctors in Queensland, with prescriptions often given for conditions there is little evidence medicinal cannabis can treat, new research reveals. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Veriheal

MARCH 2, 2024

In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.

Legalization 110

Legalization Epilepsy Clinical Trials THC 110

Cannabis Law Report

AUGUST 21, 2019

The National Institute for Health and Care Excellence (NICE) reviewed evidence for the benefits and costs of cannabis-based medicinal products and drew up guidance for health professionals and the public. It also said the children’s experiences on medicinal cannabis in the should be taken into account as evidence of how well the drug works.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81